Linking dementia research to policy: An example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment
Free accessEditorialFirst published online March, 2006
Linking dementia research to policy: An example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment
1. NCA Tracking Sheet for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG- 00088R). Available online at: https://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=104.
2.
2. Matchar DM, Kulasingam SL, McCrory DC, et al.: Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia: Task Order No. 7. Prepared by Duke University under Contract No. 290-97-0014. Rockville, MD: Agency for Health Care Policy and Research, February 2002. Available online at: http.:www.cms.hhs.gov/coveragedownload/id64.pdf.
3.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC; American Psychiatric Association, 1994.
4.
4. Small GW, Rabins PV, Barry PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA. 1997; 278: 1363-1371.
5.
5. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984; 34: 939-944.
6.
6. Knopman DS, DeKosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2001; 56: 1143-1153.
7.
7. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al.: FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000; 41: 1920-1928.
8.
8. Bookheimer SY, Strojwas MH, Cohen MS, et al.: Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000; 343: 450-456.
9.
9. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001; 286: 2120-2127.
10.
10. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2000; 97: 6037-6042.
11.
11. Kulasingam SL, Samsa GP, Zarin DA, et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision-analysis. Value Health. 2003; 6: 542-550.
12.
12. Doody RS, Stevens JC, Beck C, et al.: Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56: 1154-1166.
13.
13. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003; 290: 1624-1632.
